How occupational chemical and radiation exposure can cause, worsen, or trigger genetic diseases across generations
Consider a family where both parental lineages carry exposure to military and industrial toxicants, including dioxin (Agent Orange), ionizing radiation, and hydrazine-based rocket propellant, acquired through service or employment across nuclear energy and aerospace programs. The family then settles and raises children in an area where it was not yet publicly known that naturally occurring asbestos, hexavalent chromium, and ammonium perchlorate were present in the local soil and groundwater. That is at least six distinct mutagenic or endocrine-disrupting agents converging on one family's gene pool from both sides, across two generations, compounded by chronic environmental contamination throughout the children's development.
When the children in that scenario develop clusters of conditions spanning tuberous sclerosis, polycystic kidney disease, neurofibromatosis, brain tumors, white matter abnormalities, pseudotumor cerebri, scoliosis, degenerative disk disease, spina bifida, endometriosis, arthritis, cognitive and psychiatric disorders, vision problems, reproductive difficulties, and digit or limb abnormalities, these are not coincidental. The conditions share overlapping molecular pathways, and every exposure listed above damages DNA through mechanisms known to disrupt those same pathways. This document maps the connections between the diseases, grades the evidence linking each exposure to each condition, explains how mutagenic damage compounds across generations, catalogs available and experimental treatments, and lists legal and financial resources.
Each condition in the diagram below is grouped by the molecular pathway or developmental system connecting it to the others. Circles are clickable for detail on each disease, colored lines show the research basis for each connection, and legend labels filter by pathway type.
Each tab below shows a single toxic substance and the diseases it is linked to. Thicker, redder lines mean stronger evidence (large epidemiological studies, animal studies with dose-response, or VA-recognized presumptive conditions). Thinner blue lines mean the connection is newer or based on smaller studies and biological plausibility. Click any line or disease name for a summary of the evidence.
This diagram shows the full chain from exposure to disease. Toxic substances enter the body and cause damage through three routes: direct DNA mutation, epigenetic reprogramming (changing which genes are active without altering the sequence), and hormone disruption. That damage lands on genes that may already be weakened by inherited mutations. The result is disease clusters that no single exposure or single gene could explain on its own.
Hexavalent chromium (Cr VI) enters cells disguised as a nutrient (it looks like sulfate to the cell's transport system), then gets chemically reduced inside the cell, producing reactive chromium ions that physically bond to the DNA strand. These bonds, called crosslinks, jam the machinery that copies DNA during cell division. The cell's repair systems try to fix the damage, but they make errors in the process, and those errors become permanent mutations.
Ionizing radiation (from nuclear materials, X-rays, or radioactive waste) snaps the DNA strand in two. A single break is usually fixable. A double-strand break, where both rails of the DNA ladder get cut at nearly the same spot, is much harder to repair. The cell often stitches it back together with pieces missing or rearranged. If the break happens in the middle of a gene, that gene may stop working.
Dioxin (the active poison in Agent Orange) binds to a receptor inside the cell called AhR (aryl hydrocarbon receptor), which then moves into the nucleus and changes which genes get turned on and off. This doesn't always mutate the DNA sequence itself, but it can permanently alter the chemical tags (methyl groups) that sit on top of DNA and control gene activity. These tags can be passed from parent to child. A father exposed to dioxin in Vietnam can pass altered gene-regulation patterns to a daughter born twenty years later in Ohio.
Hydrazine and UDMH (rocket fuel components) are alkylating agents. They stick small chemical groups onto DNA bases, which causes the bases to mispair during copying. A "G" that should pair with "C" instead pairs with "T," and the wrong letter gets locked into the sequence permanently.
Ammonium perchlorate doesn't attack DNA directly. It blocks the thyroid gland from absorbing iodine by clogging the same transporter that iodine uses to get into thyroid cells. Without iodine, the thyroid can't make thyroid hormone. During pregnancy, thyroid hormone is required for the fetal brain to build its white matter (the insulation on nerve fibers) and for the neural tube (the structure that becomes the spine and brain) to close properly. A mother with suppressed thyroid function during the first trimester may have a child with spina bifida, white matter abnormalities, or cognitive deficits, even though neither the mother's nor the child's DNA was directly damaged.
Asbestos fibers are physically small enough to penetrate individual cells. Once inside, they can't be broken down. The cell's immune response to the stuck fiber produces a continuous flood of reactive oxygen species (free radicals) that damage nearby DNA over months and years. The body's inflammatory alarm system (NF-kB pathway) stays permanently activated, which promotes both cancer and autoimmune-type conditions.
A developing embryo copies DNA at an extraordinary rate. In the first 8 weeks of pregnancy, a single fertilized egg divides into billions of cells, and each division requires a complete copy of all 3 billion DNA base pairs. Errors during this period are amplified because every daughter cell inherits the mistake. A mutation that hits during week 3, when the neural tube is forming, can produce spina bifida. A mutation during week 5, when limb buds are growing, can produce extra or malformed fingers. A mutation in a tumor-suppressor gene like TSC2 or NF1 can produce tumors that don't appear until childhood or adulthood, because the gene's job is to prevent uncontrolled growth, and that growth goes unchecked once the gene is disabled.
Some birth defects come from the father's damaged sperm rather than from anything that happened during pregnancy. Radiation and alkylating agents (chromium, hydrazine) can mutate DNA in sperm cells years before conception. The child inherits the mutation at the moment of fertilization. This is one way a father's workplace exposure can produce disease in a child who was never near the workplace.
Dioxin adds a third pathway. It can alter the epigenetic tags on sperm DNA without changing the sequence itself. Animal studies showed these altered tags persisting three generations deep: the exposed animal's great-grandchildren still carried the changes despite never being exposed. A grandfather's workplace exposure can affect a grandchild's health even though the grandchild's DNA sequence is normal (Manikkam et al., 2012).
Most safety studies test one chemical at a time. A worker at a nuclear facility or aerospace plant was almost never exposed to just one substance. A typical exposure profile might include ionizing radiation from nuclear materials, hexavalent chromium from metal plating and alloys, ammonium perchlorate from solid rocket propellant, hydrazine from liquid fuel systems, and naturally occurring asbestos in the local geology (common in parts of Southern California, for example).
These substances attack DNA through different mechanisms. Radiation breaks strands. Chromium crosslinks them. Hydrazine mislabels bases. Dioxin reprograms which genes are active. When all of these hit the same cell, the repair systems get overwhelmed. A cell can usually fix a single double-strand break, but not if its mismatch repair machinery is already jammed by chromium crosslinks and its gene regulation has been scrambled by dioxin.
Many of the genetic diseases discussed here — tuberous sclerosis, neurofibromatosis, polycystic kidney disease — follow Knudson's two-hit hypothesis. Every person carries two copies of each gene, one from each parent. A single broken copy is usually survivable because the remaining good copy compensates. Disease manifests only when the second copy is also lost, whether through a new mutation from environmental exposure, radiation damage, or ordinary replication error during cell division. Environmental toxicants that raise the background mutation rate across the genome make loss of that second copy substantially more likely in any given cell over a lifetime.
Beyond the conditions mapped in the diagrams above, individuals carrying these genetic mutations or with significant parental toxic exposure face elevated risk for a broader set of problems. Several are detectable on routine bloodwork or incidental imaging; others require targeted screening that most providers won't order without specific prompting.
Hypertension appears in up to 60-70% of adults with ADPKD, often a decade before kidney function declines. The growing cysts compress the blood vessels inside the kidney and activate the renin-angiotensin system, which raises blood pressure. Any adult with polycystic kidneys should have blood pressure monitored regularly, because uncontrolled hypertension accelerates cyst growth and raises the already-elevated risk of intracranial aneurysm rupture.
Aortic and arterial abnormalities are seen in both NF1 (renal artery stenosis, moyamoya-like vasculopathy) and in connective tissue overlap syndromes associated with some of these genetic conditions. NF1 patients have a documented 7-fold increase in cardiovascular mortality compared to the general population (Rasmussen et al., 2001).
Cardiomyopathy from dioxin exposure has been documented in animal studies and in case reports from industrial accidents (Seveso, Italy, 1976). Dioxin activates AhR in cardiac tissue, which disrupts mitochondrial function in heart muscle cells.
Thyroid cancer risk is elevated after ionizing radiation exposure. The thyroid gland concentrates iodine, and when radioactive iodine (I-131, a common fission product) gets into the body, the thyroid absorbs it and receives a concentrated dose. The Chernobyl data showed a 5- to 10-fold increase in thyroid cancer in exposed children (Cardis et al., 2005). Perchlorate exposure paradoxically may be protective against radioiodine (by blocking uptake), but this has not been tested in a combined-exposure scenario.
Autoimmune thyroiditis (Hashimoto's disease) is elevated in populations exposed to radiation and dioxin. The chronic inflammation from either exposure can cause the immune system to attack the thyroid. This compounds the thyroid suppression from perchlorate, creating a double hit on thyroid function.
Pheochromocytoma (adrenal gland tumors that produce adrenaline) occurs in about 1% of NF1 patients. These cause episodes of severe high blood pressure, rapid heartbeat, sweating, and headache. They are treatable if caught, dangerous if missed.
Diabetes risk is elevated in people with chronic inflammation from any cause, and specifically in people with ADPKD (which can involve pancreatic cysts) and in dioxin-exposed populations. The Seveso Women's Health Study found a dose-dependent increase in diabetes risk with dioxin exposure (Consonni et al., 2008).
Hearing loss is the primary presenting symptom of NF2, caused by vestibular schwannomas compressing the hearing nerve. It also occurs in NF1 (from brainstem gliomas or auditory pathway involvement) and as a late effect of radiation exposure and certain chemotherapy drugs (cisplatin in particular). Tinnitus (ringing in the ears) may be the first sign.
Peripheral neuropathy (numbness, tingling, pain in hands and feet) can result from plexiform neurofibromas compressing nerves in NF1, from chemotherapy for brain tumors, from chronic inflammation, and from direct toxic effects of hexavalent chromium and hydrazine on peripheral nerves.
Malignant peripheral nerve sheath tumors (MPNSTs) are the most feared complication of NF1. Plexiform neurofibromas have an 8-13% lifetime risk of malignant transformation. Warning signs include rapid growth of an existing neurofibroma, new pain in a previously painless mass, and change in texture from soft to hard. MPNSTs are aggressive and require immediate surgical evaluation.
Renal cell carcinoma risk is elevated in both ADPKD and in people with chronic kidney inflammation from any cause, including chemical exposure.
Leukemia risk is elevated after ionizing radiation and after exposure to benzene (common in petroleum-based solvents used alongside the other chemicals in aerospace settings). Radiation-induced leukemia has the shortest latency of radiation-related cancers, appearing as early as 2-5 years after exposure.
Breast cancer risk is elevated in women with NF1 (Seminog & Goldacre, 2015, found a 3.5-fold increase) and in radiation-exposed populations, especially those exposed before age 30.
Chronic fatigue is reported at high rates across almost every condition listed in this document. It can result from chronic inflammation, thyroid dysfunction, medication side effects, chronic pain, sleep disruption from headaches (pseudotumor cerebri), sleep apnea (common in NF1 due to airway neurofibromas), or depression. It is often the most disabling symptom that patients report, and it is the one most often dismissed by providers.
PTSD and intergenerational trauma are present in families of veterans and industrial workers who watched their own health decline and then saw their children develop unexplained medical problems. The psychological burden of believing your work caused your child's illness is distinct from the medical burden of the illness itself, and it needs separate treatment.
Treatments are listed by the condition they target. Some of these are FDA-approved and covered by insurance. Others are in clinical trials and require enrollment. A few are early-stage research with no human trials yet. All links were verified at time of writing (March 2026) but clinical trial status changes frequently.
Everolimus (Afinitor) is FDA-approved for TSC-associated subependymal giant cell astrocytomas (SEGAs), TSC-associated renal angiomyolipomas, and TSC-associated partial-onset seizures. It blocks the mTOR pathway that drives tumor growth in all of these. Side effects include mouth sores, immunosuppression, and impaired wound healing. It does not cure the underlying genetic defect, so tumors regrow if the drug is stopped.
Sirolimus (Rapamune) is the original mTOR inhibitor. It is used off-label for LAM (lymphangioleiomyomatosis) in women with TSC and has been tested in PKD. The RAPTOR trial showed it slowed kidney growth in ADPKD but did not reach statistical significance for GFR preservation at the dose tested.
Tolvaptan (Jynarque) is FDA-approved specifically for ADPKD. It works through a different mechanism (vasopressin receptor blockade, not mTOR) and slows cyst growth by about 50% over three years. It requires regular liver function monitoring because of hepatotoxicity risk. It is expensive (roughly $13,000/month in the US) but most patients access it through manufacturer assistance programs.
Experimental: mTOR inhibitors are being studied for endometriosis in early-phase trials, based on the shared mTOR overactivation in endometriotic tissue and PKD cysts. Search ClinicalTrials.gov for endometriosis + mTOR.
Selumetinib (Koselugo) was FDA-approved in 2020 for children aged 2+ with NF1 who have symptomatic, inoperable plexiform neurofibromas. It blocks the MEK enzyme in the Ras-MAPK pathway that neurofibromin normally controls. In the Phase II trial, 70% of patients had tumor shrinkage of at least 20%. Side effects include skin rash, GI problems, and elevated creatine kinase.
Experimental: MEK inhibitors are being tested in adults with NF1 plexiform neurofibromas (the FDA approval is currently pediatric only), for NF1-associated low-grade gliomas, and for cutaneous neurofibromas (the small skin bumps). The NF Clinical Trials Consortium runs most of these. Search ClinicalTrials.gov for neurofibromatosis + MEK.
NFX-179 is a topical MEK inhibitor being developed specifically for cutaneous neurofibromas (applied as a cream rather than taken orally). Phase II trials are ongoing.
Bevacizumab (Avastin) is used off-label for NF2-associated vestibular schwannomas. It blocks VEGF (vascular endothelial growth factor), which these tumors depend on for blood supply. About 40-50% of patients show tumor shrinkage, and many more have hearing stabilization. It requires IV infusion every 2-3 weeks. Side effects include hypertension, proteinuria, and impaired wound healing.
Bevacizumab has also been used in refractory pseudotumor cerebri (cases that don't respond to acetazolamide and weight loss) based on the role of VEGF in dural venous sinus abnormalities. This use is highly experimental and limited to case reports.
No gene therapy is currently FDA-approved for TSC, NF, or PKD. Several approaches are in development.
For NF1: antisense oligonucleotides and gene replacement strategies are in preclinical work. The Children's Tumor Foundation funds much of this pipeline.
For PKD: CRISPR-based correction of PKD1 mutations has been demonstrated in cell cultures and organoid models. Delivery to enough kidney cells in a living person remains the main obstacle. The PKD Foundation tracks the pipeline at their research page.
For TSC: mRNA-based approaches to restore tuberin (the TSC2 protein) are in preclinical development, drawing on the same mRNA delivery technology used for COVID vaccines.
Search active gene therapy trials: TSC gene therapy | NF gene therapy | PKD gene therapy
Acetazolamide (Diamox) is the first-line drug. It reduces cerebrospinal fluid production. The IIHTT trial (Wall et al., 2014) showed it preserved visual fields when combined with weight loss. Side effects include tingling in the hands and feet, fatigue, kidney stones, and altered taste.
Topiramate (Topamax) is second-line. It also reduces CSF production and has the secondary benefit of promoting weight loss, which is relevant because obesity is a major risk factor for IIH.
Venous sinus stenting is a newer interventional procedure for patients with venous sinus stenosis (narrowing of the veins that drain blood from the brain). A wire mesh stent is placed inside the narrowed vein to hold it open. This reduces brain pressure without drugs. Long-term data is still being collected, but early results are favorable (Dinkin & Patsalides, 2017). Available at specialized neurovascular centers.
Optic nerve sheath fenestration is a surgical option when vision loss is the primary threat. A small window is cut in the membrane around the optic nerve to let fluid drain and reduce pressure on the nerve. It protects vision but does not treat headaches.
Elagolix (Orilissa) and relugolix-estradiol-norethindrone (Myfembree) are FDA-approved GnRH antagonists that suppress estrogen production, shrinking endometrial implants. They cause menopause-like side effects and have time limits on use due to bone density loss.
Laparoscopic excision surgery remains the gold standard for diagnosis and treatment. Excision (cutting out the implants) has better long-term outcomes than ablation (burning). Finding a surgeon trained in excision rather than ablation is important and not always easy. The Nancy's Nook Endometriosis Education site maintains a list of vetted excision surgeons.
Experimental: dichloroacetate (DCA), a metabolic drug, is being tested for endometriosis based on the observation that endometriotic cells have abnormal mitochondrial metabolism similar to cancer cells. Early results from Edinburgh (Horne et al.) are promising. Also watch for mTOR inhibitor trials mentioned above.
Dystrophic scoliosis in NF1 usually requires surgical fusion because bracing is ineffective for this type. Vertebral body tethering (VBT) is a newer, less invasive approach that uses a flexible cord rather than rigid rods, allowing the spine to continue growing. It is available at select pediatric spine centers and works best in patients who are still growing. Not all NF1 scoliosis curves are suitable for VBT; the dystrophic changes in the vertebrae themselves can limit options.
Fetal surgery for myelomeningocele is now available at multiple centers following the MOMS trial (Adzick et al., 2011), which showed that operating on the fetal spine before birth (at 19-25 weeks) reduced the need for shunting by half and improved motor outcomes at 30 months. This is relevant for future pregnancies in families with known exposure-related risk. Centers performing this include CHOP, Vanderbilt, Texas Children's, and UCSF.
Experimental: stem cell patches applied during fetal surgery are in Phase I trials, aiming to regenerate some of the nerve tissue damaged by the open lesion. Search ClinicalTrials.gov for myelomeningocele + stem cell.
The PACT Act (Sergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics Act), signed August 2022, is the largest expansion of VA benefits for toxic-exposed veterans in decades. It covers Agent Orange, burn pits, radiation, and other military toxic exposures. It creates presumptive service connections for over 20 conditions, meaning you don't have to prove your specific exposure caused your specific disease, only that you served in the right place and time and have the condition.
VA Agent Orange benefits and presumptive conditions
VA ionizing radiation exposure benefits
VA hazardous materials exposure (all types)
Spina bifida in children of Vietnam-era veterans is already a presumptive condition under existing VA law (38 U.S.C. § 1805), separate from the PACT Act. Benefits include a monthly monetary allowance and VA healthcare for the affected child.
If the exposure occurred in a civilian workplace (nuclear plant, aerospace facility, chemical manufacturing), the legal path is usually a toxic tort lawsuit or workers' compensation claim. These cases require documentation of the exposure (employment records, dosimetry badges, industrial hygiene reports) and medical evidence linking the exposure to the disease.
Camp Lejeune Justice Act (part of the PACT Act) specifically covers water contamination at Marine Corps Base Camp Lejeune from the 1950s through 1987. If you or a family member lived or worked at Camp Lejeune during that period, you can file a claim regardless of when the illness appeared.
For Rocketdyne/Santa Susana Field Laboratory (SSFL) exposure specifically, ongoing litigation and cleanup disputes have produced significant case law. The Boeing Company (which acquired Rocketdyne) has faced multiple lawsuits from former workers and surrounding communities.
Finding a lawyer: Look for firms that specialize in toxic tort, environmental exposure, or occupational disease. National firms with track records in this area include:
Baum Hedlund Aristei & Goldman (toxic exposure, including SSFL/Rocketdyne cases)
Simmons Hanly Conroy (asbestos, environmental contamination)
Weitz & Luxenberg (Agent Orange, toxic exposure, mesothelioma)
The DOJ Environment and Natural Resources Division handles federal enforcement actions against polluters. If a government contractor caused the exposure, the Federal Tort Claims Act may apply.
State bar associations maintain referral services for certified specialists in environmental and toxic tort law. Most toxic tort attorneys work on contingency (no fee unless they win).
TSC Alliance provides a financial assistance program, connects patients with clinical trials, and maintains a directory of TSC clinics.
Children's Tumor Foundation (for NF) funds research, maintains a clinical trial registry, and runs the NF Clinic Network with over 60 affiliated centers.
PKD Foundation provides educational resources, clinical trial matching, and connects patients with PKD Centers of Excellence.
Endometriosis Foundation of America provides educational resources and physician directory.
Spina Bifida Association provides healthcare guidelines, clinic directory, and advocacy resources.
Intracranial Hypertension Research Foundation provides patient education for pseudotumor cerebri and connects patients with specialists.
For clinical trial enrollment: ClinicalTrials.gov is the primary registry. Many trials cover travel expenses, provide the drug at no cost, and pay for associated medical monitoring. Ask the trial coordinator about financial support before assuming you can't afford to participate.
Manufacturer patient assistance programs:
Novartis (maker of Afinitor/everolimus): Novartis Patient Assistance
Otsuka (maker of Jynarque/tolvaptan): Otsuka Patient Assistance
Alexion/AstraZeneca (maker of Koselugo/selumetinib): Alexion Patient Services
Adzick NS et al. (2011). A randomized trial of prenatal versus postnatal repair of myelomeningocele. N Engl J Med, 364(11):993-1004. PubMed 21306277
Boffetta P et al. (2014). Occupational exposure to asbestos and risk of glioma. J Neurooncol. PubMed 24488446
Brook-Carter PT et al. (1994). Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease. Nat Genet, 8(4):328-332. PubMed 7894481
Cardis E et al. (2005). Risk of thyroid cancer after exposure to 131I in childhood. J Natl Cancer Inst, 97(10):724-732. PubMed 15900042
Consonni D et al. (2008). Mortality in a population exposed to dioxin after the Seveso, Italy, accident in 1976. Am J Epidemiol, 167(7):847-858. PubMed 18192279
Creange A et al. (1999). Neurological complications of neurofibromatosis type 1 in adulthood. Brain, 122(3):473-481. PubMed 10094256
Dinkin MJ, Patsalides A (2017). Venous sinus stenting in idiopathic intracranial hypertension. J Neuroophthalmol, 37(2):113-121. PubMed 27636748
Fike JR et al. (2009). Radiation response of neural precursor cells. Neurosurg Clin N Am, 20(1):15-23. PubMed 19064176
Gibb HJ et al. (2015). Utility of recent studies to assess the National Research Council 2001 estimates of cancer risk from ingested chromium. Environ Health Perspect, 123(2):109-119. PubMed 25325104
Hardell L et al. (2007). Exposure to pesticides as risk factor for non-Hodgkin's lymphoma and hairy cell leukemia. Leuk Lymphoma, 48(7):1278-1289. PubMed 17613755
Harris HR et al. (2016). Endometriosis and the risks of systemic lupus erythematosus and rheumatoid arthritis. Ann Rheum Dis, 75(7):1279-1284. PubMed 26238146
Heller DS et al. (1996). Asbestos exposure and ovarian fiber burden. Am J Ind Med, 29(5):435-439. PubMed 8732915
Kleinschmidt JJ et al. (2000). Idiopathic intracranial hypertension: relationship to depression, anxiety, and quality of life. Neurology, 54(2):319-324. PubMed 10668690
Korevaar TIM et al. (2016). Association of maternal thyroid function during early pregnancy with offspring IQ and brain morphology in childhood. Lancet Diabetes Endocrinol, 4(1):35-43. PubMed 26497402
Krueger DA et al. (2010). Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med, 363(19):1801-1811. PubMed 21047224
Kuo CC et al. (2018). The association of occupational chromium exposure with neurological symptoms. Neurotoxicology, 68:92-100.
Kumar S, Sagar A (2020). Effects of hexavalent chromium on male reproductive system. Environ Sci Pollut Res, 27(15):17329-17340.
Le TN, Johansson A (2001). Impact of chemical warfare with Agent Orange on women's reproductive lives in Vietnam. Reprod Health Matters, 9(18):156-164. PubMed 11765393
Manikkam M et al. (2012). Dioxin (TCDD) induces epigenetic transgenerational inheritance of adult onset disease and sperm epimutations. PLoS ONE, 7(9):e46249. PubMed 23049995
National Academies of Sciences (2018). Veterans and Agent Orange: Update 11. Washington, DC: National Academies Press. NAP catalog 25137
Ngo AD et al. (2006). Association between Agent Orange and birth defects. Int J Epidemiol, 35(5):1220-1230. PubMed 16543362
Padmanabhan R (2006). Etiology, pathogenesis and prevention of neural tube defects. Congenit Anom (Kyoto), 46(2):55-67. PubMed 16732763
Pfau JC et al. (2005). Autoantibodies and asbestos exposure in Libby, Montana. Am J Med, 118(4):428-432. PubMed 15808142
Preston DL et al. (2007). Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res, 168(1):1-64. PubMed 17722996
Rasmussen SA et al. (2001). Mortality in neurofibromatosis 1. Am J Hum Genet, 68(5):1110-1118. PubMed 11283797
Rier SE et al. (1993). Endometriosis in rhesus monkeys following chronic exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Fundam Appl Toxicol, 21(4):433-441. PubMed 8253297
Schull WJ (1997). Brain damage among individuals exposed prenatally to ionizing radiation. Ann ICRP, 27(1-3):63-68.
Seminog OO, Goldacre MJ (2015). Risk of benign tumours of nervous system and of malignant neoplasms in people with neurofibromatosis. Br J Cancer, 112(9):1570-1574. PubMed 25791875
Sharma DC et al. (2012). Chromium and birth defects in India. Lancet, 379(9833):2200-2201.
Toth B (1977). Tumorigenicity of 1,1-dimethylhydrazine in Swiss mice. Int J Cancer, 20(4):573-578. PubMed 908469
Wall M et al. (2014). Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension. JAMA, 311(16):1641-1651. PubMed 24756514
Zoeller RT, Rovet J (2004). Timing of thyroid hormone action in the developing brain. Trends Endocrinol Metab, 15(10):479-486. PubMed 15541647